CTLA4 was found to be significantly downregulated in both the tbLN and spleen of tbLN treated mice suggestive of superior drug distribution at site critical to generating anti-cancer effect upon localized delivery of anti-CTLA4 mAb (Fig. 2 I – L). The gene discussed is CTLA4; the disease is cancer.